Defactinib (Synonyms: VS-6063; PF-04554878)

Name: Defactinib
Brand: MedChemExpress
SKU: HY-12289
Rating: 5.0 (41 reviews)

Cat. No.: HY-12289 Purity: 99.87%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.

For research use only. We do not sell to patients.

Defactinib Chemical Structure

CAS No. : 1073154-85-4

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 41 publication(s) in Google Scholar

Other Forms of Defactinib:

Defactinib hydrochloride In-stock
Defactinib-d₆ Get quote

40 Publications Citing Use of MCE Defactinib

: Defactinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Jul 28;37(1):175. [Abstract]; Western blot verified the inhibition of FAK Y397 phosphorylation via Defactinib in MCF7-YAP-S127A and MDA-MB-231 cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.

IC₅₀ & Target

FAK^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A375P	GI₅₀	5.94 μM Compound: VS-6063; PF-04554878	Antiproliferative activity against human A375P cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human A375P cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
A549	IC₅₀	4.09 μM Compound: 7	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
BXPC-3	IC₅₀	3.25 μM Compound: 7	Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
HCT-116	IC₅₀	2.65 μM Compound: 5; VS-6063	Antiproliferative activity against human HCT116 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31129452]
HCT-116	GI₅₀	9.13 μM Compound: VS-6063; PF-04554878	Antiproliferative activity against human HCT-116 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HCT-116 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
HCT-15	IC₅₀	4.36 μM Compound: 7	Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
HEK293	IC₅₀	4.07 μM Compound: 7	Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
HepG2	IC₅₀	3.69 μM Compound: 7	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
HUVEC	IC₅₀	3.24 μM Compound: 7	Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
L02	IC₅₀	4.66 μM Compound: 7	Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
MCF-10A	IC₅₀	18.42 μM Compound: 5; VS-6063	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31129452]
MCF7	IC₅₀	5.81 μM Compound: 7	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
MCF7	IC₅₀	8.97 μM Compound: 5; VS-6063	Antiproliferative activity against human MCF7 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31129452]
MDA-MB-231	GI₅₀	11.45 μM Compound: VS-6063; PF-04554878	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
MDA-MB-231	IC₅₀	3.75 μM Compound: 7	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
PANC-1	IC₅₀	3.48 μM Compound: 7	Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34091209]
PC-3	IC₅₀	> 20 μM Compound: 5; VS-6063	Antiproliferative activity against human PC3 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31129452]
U-87MG ATCC	IC₅₀	10.21 μM Compound: 5; VS-6063	Antiproliferative activity against human U87MG cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human U87MG cells overexpressing FAK assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31129452]

In Vitro

Defactinib (VS-6063) inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner. RPPA data shows that Defactinib reduces levels of AKT and YB-1 in taxane-resistant cell lines. The expression of pFAK (Tyr397) is statistically significantly inhibited by Defactinib in a dose-dependent manner in all cell lines. Defactinib inhibits pFAK (Tyr397) expression within 3 hours, with a gradual return of expression by 48 hours^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Defactinib (VS-6063) doses of 25 mg/kg twice a day or greater statistically significantly inhibits pFAK (Tyr397) at 3 hours, with return of expression noted by 24 hours. Therefore, administration of Defactinib at 25 mg/kg twice a day is selected as the dosing schedule for subsequent therapy experiments. For therapy experiments, female nude mice bearing HeyA8 tumors in the peritoneal cavity are randomly divided into 4 groups (n=10 per group): 1) vehicle orally twice daily and phosphate-buffered saline intraperitoneally weekly (control); 2) Defactinib 25 mg/kg orally twice daily; 3) PTX intraperitoneally weekly; and 4) both VDefactinib 25 mg/kg orally twice daily and PTX intraperitoneally weekly. There is an 87.4% reduction in tumor weight by PTX monotherapy in the HeyA8 model, and combination therapy resulted in the greatest tumor weight reduction, with a 97.9% reduction (P=0.05 compared with PTX). In the SKOV3ip1 model, a 92.7% tumor weight reduction is observed in the combination group compared with PTX (P<0.001)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

510.49

Formula

C₂₀H₂₁F₃N₈O₃S

CAS No.

1073154-85-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(NC)C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=NC=CN=C3N(C)S(=O)(C)=O)=N2)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (97.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9589 mL	9.7945 mL	19.5890 mL
5 mM	0.3918 mL	1.9589 mL	3.9178 mL
10 mM	0.1959 mL	0.9795 mL	1.9589 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline
Solubility: 2.5 mg/mL (4.90 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.5 mg/mL (4.90 mM); Suspended solution; Need ultrasonic
Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (9.79 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (249 KB) LCMS (112 KB) Elemental Analysis Report (107 KB)

Handling Instructions (2659 KB)

References

[1]. Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. [Content Brief]

Animal Administration
^[1]

Mice^[1]
To determine the antitumor effects of Defactinib, SKOV3ip1, SKOV3-TR, HeyA8, and HeyA8-MDR cells are injected intraperitoneally. One week after tumor cell injection, mice are randomly assigned to 4 groups of 10 mice (control, PTX alone, Defactinib alone, and PTX with Defactinib); treatment is initiated at 3-4 weeks following injection. PTX at 2 mg/kg (SKOV3ip1 and SKOV3-TR) or 2.5 mg/kg (HeyA8 and HeyA8-MDR) is given intraperitoneally weekly; Defactinib at 25 mg/kg is given orally twice every day. Control mice received HBSS intraperitoneally once a week and vehicle orally twice every day. Mice are monitored daily for adverse effects of therapy and are killed on day 35 (SKOV3ip1 or SKOV3-TR), day 28 (HeyA8 or HeyA8-MDR), or when any of the mice seemed moribund. Total body weight, tumor incidence and mass, and the number of tumor nodules are recorded. Tumors are either fixed in formalin or embedded in paraffin or snap frozen in optimal cutting temperature (OCT) compound in liquid nitrogen.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9589 mL	9.7945 mL	19.5890 mL	48.9726 mL
	5 mM	0.3918 mL	1.9589 mL	3.9178 mL	9.7945 mL
	10 mM	0.1959 mL	0.9795 mL	1.9589 mL	4.8973 mL
	15 mM	0.1306 mL	0.6530 mL	1.3059 mL	3.2648 mL
	20 mM	0.0979 mL	0.4897 mL	0.9795 mL	2.4486 mL
	25 mM	0.0784 mL	0.3918 mL	0.7836 mL	1.9589 mL
	30 mM	0.0653 mL	0.3265 mL	0.6530 mL	1.6324 mL
	40 mM	0.0490 mL	0.2449 mL	0.4897 mL	1.2243 mL
	50 mM	0.0392 mL	0.1959 mL	0.3918 mL	0.9795 mL
	60 mM	0.0326 mL	0.1632 mL	0.3265 mL	0.8162 mL
	80 mM	0.0245 mL	0.1224 mL	0.2449 mL	0.6122 mL

Defactinib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Defactinib1073154-85-4VS-6063 PF-04554878VS6063VS 6063PF04554878PF 04554878PF-04554878FAKPTK2 protein tyrosine kinase 2PTK2Focal adhesion kinaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Defactinib (Synonyms: VS-6063; PF-04554878)

Customer Review

Other Forms of Defactinib:

Defactinib Related Antibodies

40 Publications Citing Use of MCE Defactinib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Defactinib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Defactinib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report